A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

Summary Melanoma continues to be a major health problem with no effective therapy. Melanocytes, both benign and malignant, express many anti-apoptotic factors. Survivin is a member of the family of inhibitors of apoptosis proteins (IAP) and is preferentially expressed in tumor cells, including melan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2011-02, Vol.29 (1), p.161-166
Hauptverfasser:	Lewis, Karl D., Samlowski, Wolfram, Ward, John, Catlett, Joseph, Cranmer, Lee, Kirkwood, John, Lawson, David, Whitman, Eric, Gonzalez, Rene
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antigens Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Apoptosis Cancer therapies Cell cycle Chemotherapy Creatinine Disease-Free Survival Drug dosages Female Gene expression Hepatitis Humans Imidazoles - administration & dosage Imidazoles - adverse effects Imidazoles - therapeutic use Inhibitor of Apoptosis Proteins Lymphoma Male Medicine Medicine & Public Health Melanoma Melanoma - drug therapy Melanoma - pathology Melanoma - surgery Metastasis Microtubule-Associated Proteins - antagonists & inhibitors Microtubule-Associated Proteins - metabolism Middle Aged Naphthoquinones - administration & dosage Naphthoquinones - adverse effects Naphthoquinones - therapeutic use Neoplasm Staging Oncology Pharmaceuticals Pharmacology/Toxicology Phase II Studies Prostate cancer Proteins R&D Research & development Response rates Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - pathology Skin Neoplasms - surgery Studies Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!